BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  VALNEVA Signs $39.6M IXIARO Supply Contract With U.S. Government

  The new agreement will supplement the initial contract Valneva signed with the US military in March 2016 as the maximum quantity of doses allowed in the precedent contract was reached earlier than expected.

  November 8, 2017

   · 

  5 min read
• Business

  Amedisys Reports Third Quarter 2017 Financial Results

  Net service revenue increased $18.6 million to $380.2 million compared to $361.6 million in 2016.

  November 8, 2017

   · 

  23 min read
• Business

  Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

  Cash and cash equivalents and marketable securities as of September 30, 2017 were $43.8 million, compared to $64.1 million as of December 31, 2016.

  November 8, 2017

   · 

  10 min read
• Business

  Profound Medical Corp. Announces Third Quarter 2017 Financial Results

  For the quarter ended September 30, 2017, the Company recorded revenues of $1,465,412, with $1,452,773 from the sale of products and $12,639 from installation and training services.

  November 8, 2017

   · 

  12 min read
• Business

  ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights

  Pro forma cash, cash equivalents, investments and remaining upfront commitments totaled $154.8 million at September 30, 2017.

  November 8, 2017

   · 

  9 min read
• Business

  Alder BioPharmaceuticals Announces Third Quarter 2017 Financial and Operating Results

  Research and development expenses for the quarter ended September 30, 2017 totaled $52.2 million, compared to $29.5 million for the same period in 2016.

  November 8, 2017

   · 

  9 min read
• Business

  REVA Medical Reports Third Quarter 2017 Financial Results

  The Company initiated commercial sales of the Fantom bioresorbable scaffold and reported total billings for shipped product of $105,000 with $17,000 of revenue recognized for the third quarter of 2017 compared to no billings or revenue for the same period in 2016.

  November 8, 2017

   · 

  10 min read
• Bio NC

  RedHill Biopharma Announces Proposed Public Offering of Its American Depositary Shares

  The Company intends to use the proceeds from the offering to fund clinical development programs, for potential acquisitions, to support commercial operations and for general corporate purposes.

  November 8, 2017

   · 

  7 min read
• Business

  TESARO Announces Third-Quarter 2017 Operating Results

  TESARO reported total revenue of $142.8 million for the third quarter of 2017, compared to $17.0 million for the third quarter of 2016.

  November 8, 2017

   · 

  16 min read
• Business

  BioTelemetry Reports Third Quarter 2017 Financial Results

  Recognized highest quarterly revenue in Company’s history of $81.0 million, a 52.7% increase over the prior year driven by the acquisition of LifeWatch AG.

  November 8, 2017

   · 

  26 min read